Predict your next investment

Asset/Investment Management
skyviewslifescience.com

See what CB Insights has to offer

Investments

11

Portfolio Exits

2

About Skyviews Life Science

Skyviews Life Science is specifically designed to identify investment opportunities in companies at the growing interface between biotechnology, molecular nutrition and digital platforms that prevent the onset and facilitate the management of chronic conditions.

Skyviews Life Science Headquarter Location

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Skyviews Life Science News

BCD Bioscience Raises USD 12M In Series A

Apr 15, 2022

BDC Bioscience, a Davis, CA-based biotechnology company, raised USD 12M in Series A funding. The round was led by Acre Venture Partners, with participation from Seventure Partners iSelect Fund, Collaborative Fund and Skyviews Life Science.

Skyviews Life Science Investments

11 Investments

Skyviews Life Science has made 11 investments. Their latest investment was in Tropic Biosciences as part of their Series C on July 7, 2022.

CBI Logo

Skyviews Life Science Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/6/2022

Series C

Tropic Biosciences

$35M

No

3

3/11/2022

Series A - II

BCD Bioscience

$12M

Yes

3

7/21/2021

Series D

Vedanta Biosciences

$68M

Yes

23

7/7/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/5/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/6/2022

3/11/2022

7/21/2021

7/7/2021

5/5/2021

Round

Series C

Series A - II

Series D

Series B

Series B

Company

Tropic Biosciences

BCD Bioscience

Vedanta Biosciences

Subscribe to see more

Subscribe to see more

Amount

$35M

$12M

$68M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

3

23

10

10

Skyviews Life Science Portfolio Exits

2 Portfolio Exits

Skyviews Life Science has 2 portfolio exits. Their latest portfolio exit was MaaT Pharma on November 03, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/3/2021

IPO

$99M

Public

2

9/18/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/3/2021

9/18/2020

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

2

10

Skyviews Life Science Team

1 Team Member

Skyviews Life Science has 1 team member, including current Chief Executive Officer, Managing Partner, Stefan Catsicas.

Name

Work History

Title

Status

Stefan Catsicas

Nestle, King Abdullah University of Science and Technology, Ecole Polytechnique Federale de Lausanne, Université de Lausanne, GSK, and Scripps Research Institute

Chief Executive Officer, Managing Partner

Current

Name

Stefan Catsicas

Work History

Nestle, King Abdullah University of Science and Technology, Ecole Polytechnique Federale de Lausanne, Université de Lausanne, GSK, and Scripps Research Institute

Title

Chief Executive Officer, Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.